INDV · Indivior Pharmaceuticals, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|---|
| $1.22B – $1.29B | $1.33B | $1.24BG | $1.19B | $1.09BG | $901MG | $791M | |
| — | $240M | $246M | $231M | $174M | $151M | $127M | |
| — | $1.09B | $994M | $957M | $919M | $749M | $664M | |
| — | — | 80.23% | 80.56% | 84.08% | 83.13% | 83.94% | |
| — | $82M | $97M | $107M | $116M | $74M | $52M | |
| — | — | — | — | $236M | $218M | $192M | |
| — | — | — | — | $575M | $545M | $239M | |
| — | $589M | $634M | $612M | $565M | $466M | — | |
| — | $9M | $10M | $16M | $15M | $16M | $6M | |
| — | — | — | $919M | $1.07B | $827M | — | |
| — | $421M | $262M | $38M | -$152M | -$77M | $213M | |
| — | — | 21.15% | 3.2% | -13.91% | -8.55% | 26.93% | |
| — | $430M | $272M | $54M | -$137M | -$61M | $219M | |
| — | $27M | $45M | $41M | $35M | $27M | $27M | |
| — | $18M | $22M | $23M | $43M | $19M | — | |
| — | $393M | $239M | $20M | -$145M | -$86M | $190M | |
| — | $38M | $29M | $13M | -$19M | -$43M | -$15M | |
| — | $356M | $210M | $7M | -$126M | -$42M | $205M | |
| — | — | 16.95% | 0.59% | -11.53% | -4.66% | 25.92% | |
| — | $359M | $216M | $1M | -$124M | -$50M | — | |
| USD/shares | — | $2.88 | $1.68 | $0.05 | -$0.92 | -$0.30 | — |
| USD/shares | — | $2.79 | $1.64 | $0.05 | -$0.92 | -$0.30 | — |
| shares | — | — | 125M | 132M | 137M | 139M | — |
| shares | — | — | 128M | 133M | 137M | 139M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: $408M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 39 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $1,239,000,000 | $1,188,000,000 | $1,093,000,000 | $901,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| United States | $1,053,000,000 | $1,008,000,000 | $912,000,000 | $732,000,000 |
| Non Us | $186,000,000 | $179,000,000 | $181,000,000 | $169,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Sublocade | $856,000,000 | $756,000,000 | — | — |
| Perseris | — | — | $42,000,000 | $28,000,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $262,000,000 | $38,000,000 | -$152,000,000 | -$81,000,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | 21.1% | 3.2% | -13.9% | -9% |